Washington Post Publisher Will Lewis Steps Down After Layoffs 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SAN ANTONIO, July 19, 2017 -- bioAffinity Technologies, a privately held company advancing early-stage cancer diagnostics and precision therapeutics, announced today that it raised more than $4 million in the recently closed Series A funding.
bioAffinity Technologies is commercializing a non-invasive, early-stage lung cancer test called CyPath® Lung that detects the disease when it can be successfully treated. CyPath® is a platform technology that will be expanded beyond lung cancer to diagnose multiple cancers, including prostate and cervical. OncoSelect Therapeutics, the Company’s drug development division, focuses on commercialization of targeted therapies to treat cancer.
“We remain focused on the development of safer, more effective cancer diagnostics including CyPath® Lung, a patient-friendly test to detect lung cancer at its earliest stages when treatment is most effective,” said bioAffinity President and CEO Maria Zannes. “Series A investments will propel our lung cancer diagnostic to commercialization and further our development of additional cancer tests and novel therapeutics that will treat cancer more effectively.”
About bioAffinity Technologies
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology are conducted in bioAffinity Technologies’ laboratories and at UT Health at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
